At this point, it is important to note that the research cited above focused on patients with melanoma receiving PD-1 inhibitors who were previously treated with a CTLA-4 inhibitor, while in NSCLC, patients are rechallenged with PD-(L)1-based regimens after previous PD-axis inhibition. Here, CD274 is linked to melanoma.